Health
Novartis’ New Drug Shows Strong Results Against Malaria, Offering Hope Amid Rising Resistance
Swiss pharmaceutical company Novartis has reported promising results for its experimental malaria drug GanLum, saying it will move quickly to seek regulatory approval after a successful late-stage clinical trial. The new treatment has shown strong effectiveness not only against standard malaria strains but also against drug-resistant forms of the parasite, a growing concern in Africa and other parts of the world.
The trial involved nearly 1,700 participants across 12 African countries, comparing GanLum to existing artemisinin-based combination therapy (ACT), which has been the standard treatment for the past two decades. Four weeks after treatment, 85.3 percent of patients who received GanLum had no symptoms or detectable parasites, compared with 82.1 percent in the group that received standard care. Novartis said this translates to a cure rate of 99.2 percent for GanLum versus 96.7 percent for existing therapies.
Dr. Abdoulaye Djimdé, a professor of parasitology and mycology at the University of Science, Techniques and Technologies of Bamako, Mali, described the results as potentially “the biggest advance in malaria treatment for decades.” He noted that “drug resistance is a growing threat to Africa, so new treatment options can’t come a moment too soon.”
Malaria remains one of the world’s most serious infectious diseases. According to the World Health Organization (WHO), there were around 263 million malaria cases and 597,000 deaths globally in 2023, with Africa accounting for the vast majority. Children under five represent about three-quarters of all malaria deaths on the continent.
Current treatments rely mainly on ACT, which combines artemisinin with other drugs. However, resistance to artemisinin has begun to emerge in several African countries, including Rwanda, Uganda, and Eritrea, raising fears that progress against the disease could stall. GanLum’s formula uses two different compounds that attack the malaria parasite through separate biological mechanisms, helping it remain effective even against resistant strains.
Dr. Shreeram Aradhye, president of development and chief medical officer at Novartis, said the new treatment “has the potential to both treat the disease and block transmission.” He added that the company plans to move “as quickly as possible” to submit GanLum for regulatory approval.
The trial focused on patients with acute, uncomplicated malaria caused by Plasmodium falciparum, the most deadly and widespread malaria parasite in Africa. The research was funded partly by the European Union, Germany, and the United Kingdom, and the results were presented this week at a scientific meeting.
Dr. Alena Pance, a senior genetics lecturer at the University of Hertfordshire in the United Kingdom who was not involved in the study, called the findings “really encouraging,” though she urged further testing on severe and cerebral malaria as well as other parasite species.
If approved, GanLum could mark a major milestone in the global fight against malaria, providing a new tool to counter the rise of resistance and potentially saving hundreds of thousands of lives each year.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
